Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 45

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2013; 19(45): 8357-8365
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8357

Table 1 Demographic characteristics of the study population (n = 100) n (%)

Variables	Results
Age (mean ± SD; range, yr)	59.5 ± 11.4 (range 27-89)
Sex (male:female)	71:29
Risk factors for HCC
Chronic HBV infection	20 (20)
Chronic HCV infection	2 (2)
Hepatitis B-related cirrhosis	45 (45)
Hepatitis C-related cirrhosis	16 (16)
Alcoholic cirrhosis	9 (9)
Nonalcoholic steatohepatitis	6 (6)
Only high serum AFP levels	2 (2)
Child-Pugh score
A	94 (94)
B	5 (5)
C	1 (1)
Alpha-fetoprotein (mean ± SD; range, ng/mL)	111.6 ± 935.1 (range 0.98-8973)
< 20	84 (84)
20-200	5 (5)
> 200	3 (3)
Total bilirubin (mean ± SD; range, mg/dL)	1.43 ± 2.5 (range 0.2-17.1)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein.

Citation: Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 2013; 19(45): 8357-8365
URL: https://www.wjgnet.com/1007-9327/full/v19/i45/8357.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i45.8357

Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 2013; 19(45): 8357-8365 [PMID: 24363528 DOI: 10.3748/wjg.v19.i45.8357]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.